The purpose of this study is to find out how well the HIV medication dolutegravir gets into
different parts of the body: including blood plasma, special blood cells, and rectal tissue.
Specifically, investigators want to compare how fast dolutegravir lowers the HIV viral load
in these three different sites. In addition, investigators seek to learn if there are any
differences in how dolutegravir acts in males and females. Results of this study will provide
more information about HIV medications and their limitations. In the future, this could help
create better HIV medications that can get into these hard-to-reach places and eventually
cure HIV infection.
Phase:
Phase 4
Details
Lead Sponsor:
Emory University
Collaborators:
National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH)
Treatments:
Anti-Retroviral Agents Dolutegravir Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Triumeq